Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
Authors:
- Fangbing LiuFLFangbing Liu
- Hasini A. KalpageHKHasini A. Kalpage
- Deying WangDWDeying Wang
- Holly EdwardsHEHolly Edwards
- Maik HüttemannMaik Hüttemann
- Jun MaJMJun Ma
- Yongwei SuYSYongwei Su
- Jenna CarterJCJenna Carter
- Xinyu LiXLXinyu Li
- Lisa PolinLPLisa Polin
- Juiwanna KushnerJKJuiwanna Kushner
- Sijana H. DzinicSDSijana H. Dzinic
Open Access
Abstract
Targeting oxidative phosphorylation (OXPHOS) is a promising strategy to improve treatment outcomes of acute myeloid leukemia (AML) patients. IACS-010759 is a mitochondrial complex I inhibitor that has demonstrated preclinical antileukemic activity and is being tested in Phase I clinical trials. However, complex I deficiency has been reported to inhibit apoptotic cell death through prevention of cytochrome c release. Thus, combining IACS-010759 with a BH3 mimetic may overcome this mechanism of resistance leading to synergistic antileukemic activity against AML. In this study, we show that IACS-010759 and venetoclax synergistically induce apoptosis in OXPHOS-reliant AML cell lines and primary patient samples and cooperatively target leukemia progenitor cells. In a relatively OXPHOS-reliant AML cell line derived xenograft mouse model, IACS-010759 treatment significantly prolonged survival, which was further enhanced by treatment with IACS-010759 in combination with venetoclax. Consistent with our hypothesis, IACS-010759 treatment indeed retained cytochrome c in mitochondria, which was completely abolished by venetoclax, resulting in Bak/Bax- and caspase-dependent apoptosis. Our preclinical data provide a rationale for further development of the combination of IACS-010759 and venetoclax for the treatment of patients with AML.Keywords
Funding Information
- National Institutes of Health (P30 CA022453)
This publication has 27 references indexed in Scilit:
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199Leukemia, 2014
- Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51PLOS ONE, 2013
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myelomaLeukemia, 2013
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Enhanced normal short-term human myelopoiesis in mice engineered to express human-specific myeloid growth factorsBlood, 2013
- Galactose Enhances Oxidative Metabolism and Reveals Mitochondrial Dysfunction in Human Primary Muscle CellsPLOS ONE, 2011
- Acute myeloid leukaemia in the elderly: a reviewBritish Journal of Haematology, 2011
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid LeukemiaClinical Cancer Research, 2010
- AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3Leukemia, 2010
- RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemiaBlood, 2009